Using a monoclonal anti-tubular basement membrane antibody
Introduction
Interstitial nephritis represents an important group of kidney diseases which accounts for up to 25% of patients reaching endstage renal failure (1) . Because a mononuclear cell infiltrate is the typical histologic feature of this lesion and because antitubular basement membrane antibodies (aTBM-Ab)' are present in some cases, an autoimmune response is thought to play an important role in disease expression (2, 3) . This view has been reinforced by studies in experimental interstitial nephritis associated with aTBM-Ab. This is a well-characterized model in which pathogenic autoimmune responses have been clearly documented in rodents (4) (5) (6) (7) . We have also recently isolated and characterized from rabbits the nephritogenic antigen used in this model (8) . This current study provides new immunologic information on human interstitial nephritis associated with aTBM-Ab. Such an entity has been described in association with drugs (9) , after renal transplantion (10) , and in idiopathic form (11). The target antigen of the human autoimmune response has not been formally identified and the relationship of this human response to the model ofexperimental aTBM disease is not entirely clear.
We now report the isolation of this tubular antigen from human kidney using a relevant monoclonal aTBM-Ab affinity column. aTBM-Ab from two patients with aTBM disease specifically reacted with the isolated moiety from both human and rabbit tubular basement membrane. These human antibodies also share paratypic specificity with aTBM-Ab from rats and mice with experimental aTBM disease. Our findings establish two important links between human aTBM disease and its experimental model.
Methods
Antisera. We obtained antisera from two patients with aTBM disease. The first patient was a 36-yr-old white male who presented with endstage renal failure. Extensive evaluation did not reveal an etiology and he was placed on chronic maintenance hemodialysis. 3 mo later he received a cadaveric kidney transplant which functioned well initially. 2 mo later he presented with signs of rejection, and a biopsy of the transplanted kidney was performed. The second patient was a 27-yr-old white female who presented with acute renal failure of unknown cause. Extensive evaluation was unrevealing. Hemodialysis was instituted and a kidney biopsy was performed. In both patients light microscopy revealed interstitial nephritis with mononuclear cell and polymorphonuclear leukocyte infiltration. The glomeruli were largely normal. Immunofluorescence demonstrated linear deposition of Ig and C3 along the tubular basement membrane, and there was no glomerular staining. In addition to these two patient antisera, serum was also obtained from normal volunteers and from seven patients with acute renal disease in the absence of demonstrable aTBM-Ab. These included two patients with primary interstitial nephritis, two patients with anti-glomerular basement membrane (aGBM) disease without aTBM-Ab, two patients with lupus nephritis, and one patient with membranous glomerulonephritis. aTBMAb from SJL mice and BN rats were eluted from kidneys of animals immunized to produce aTBM disease (6, 7) .
Immunofluorescence analysis. Indirect immunofluorescence was performed with both antisera from patients with aTBM disease. The titer ofcirculating aTBM-Ab was assessed using cryostat sections ofnormal human kidney which were incubated with serial dilutions of serum. Normal human serum served as a negative control. Deposited Ig was visualized with a fluoresceinated anti-human IgG (Cappel Laboratories Inc., Cochransville, PA). Patient sera (at a 1:10 dilution) were tested on the following tissues: 6 normal human kidneys (obtained from accident victims); 48 human kidney biopsies, covering a wide spectrum of renal diseases and including two cases of nail-patella syndrome and one case of familial nephropathy (Alport's syndrome); 4 human skin biopsies; 6 human lung biopsies; normal monkey esophagus; and normal kidney tissue from C57BL mice, BN and LEW rats, guinea pigs, and NZW rabbits.
Preparation ofrenal tubular antigen. Rabbit and human renal tubular basement membranes (TBMs) were isolated by a differential sieving technique (5) . Human kidneys, which were intended for transplantation but were deemed unusable for reasons of defective vascular anatomy, were obtained from cadaveric donors. Highly enriched basement membrane fragments were isolated, sonicated, 1yophilized, and stored at -70'C. Solubilized tubular antigen (human-HSRTA; rabbit-RSRTA) was made from these 1yophilized membranes using bacterial collagenase (CLS IV; Worthington, Division of Cooper Biomedical, Inc., Malvern, PA) in the presence of protease inhibitors (12) .
Monoclonal antibody affinity chromatography. a3M-l (aTBM-Ab) and a29M-l (aTBM/aGBM-Ab) monoclonal antibodies have been described previously (8) . These were originally obtained from mice immunized with rabbit renal tubular antigen. a3M-l does not recognize glomerular basement membrane nor other renal structures. It stains the TBM of BN rats (a strain susceptible to the induction of experimental aTBM disease) but not that of LEW rats (a strain generally acknowledged to be lacking the target antigen of disease). a3M-I also binds the TBM of normal human tissue. a29M-1 recognizes both TBM and glomerular basement membrane (GBM), and stains LEW rat kidneys. The preparation and use of an a3M-1 Sepharose 4B (Pharmacia Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, NJ) immunoaffinity column has also been previously described in detail (8) . A moiety was derived from RSRTA (R3M-1) and from HSRTA (H3M-1).
Gel electrophoresis and antigen elution. 8% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) gels were performed by the slab technique of Laemmli (13) . The gel bands were developed with silver stain (14) . In some experiments, after silver staining of end lanes, selected bands in central lanes were excised and incubated with 0.1% SDS for 72 h at 4°C with constant mixing. The eluate was collected, dialyzed extensively against distilled water, and lyophilized for future use.
Solid-phase radioimmunoassay. This methodology has been previously described in detail (8) . In essence, the wells of a polyvinyl chloride microtiter plate were incubated with an antigen of interest, blocked, incubated with test antisera, and developed with the appropriate speciesspecific '25l-anti-IgG. Competitive inhibition radioimmunoassays were performed by admixing serial dilutions ofeluted kidney-bound antibodies (15) from SJL mice or BN rats with aTBM disease, or IgG from normal controls, with a dilution of human antisera which gave 50% of maximal binding reactivity. The reaction was then developed with 1251I-antihuman IgG.
Results
Immunofluorescent analysis ofa TBM-Ab. Incubation ofcryostat sections of normal human kidney with serum from either patient with aTBM disease resulted in the binding of IgG exclusively to the basement membrane ofproximal tubules and ofBowman's capsule. These sera reacted with the TBMs of all normal and pathologic human kidney specimens. Binding to the GBM was never observed. Binding was also restricted to the kidney, as no reactivity was observed with basement membranes in human lung and skin or monkey esophagus. The aTBM-Ab of both patients also localized along the basement membrane ofnormal proximal tubules and Bowman's capsule in C57BL mice, BN rats, guinea pigs, and NZW rabbits. No binding, however, was observed when normal LEW rat kidney was used as the reaction substrate. All normal human sera as well as sera from renal patients without aTBM disease failed to bind the TBM.
Isolation of H3M-1 and its recognition by human aTBM antisera. In an initial screening, solid-phase radioimmunoassay antisera from both patients with aTBM disease displayed strong and specific reactivity with R3M-1, the rabbit antigen of experimental aTBM disease (Fig. 1 A) . HSRTA was also passed over the a3M-1 immunoaffinity column. The eluate, H3M-1, was compared with R3M-1 for reactivity with the reference monoclonal a3M-I in a solid-phase radioimmunoassay (Fig. 1 B) . H3M-1 displayed '-30% ofthe reactivity with a3M-l compared with R3M-1. SDS-PAGE (Fig. 2) Since the 3M-I moiety denatures with Western blotting (data not shown), we demonstrated antibody recognition of electrophoresed material using elution techniques. The dominant band of H3M-1 was eluted in 0.1% SDS and assessed for reactivity with patient antisera containing aTBM antibodies in a solidphase radioimmunoassay. Fig. 2 so that additional comparisons could not be made. Nevertheless, the dominant 48,000-mol-wt band of H3M-I specifically reacted with patient antisera.
Sera from both patients were reactive with H3M-I up to dilutions of 1:10,000 (Fig. 3 A) . This compares with immunofluorescent titers of 1:64-1:128. Neither pooled normal human sera, nor individual sera from seven patients with acute renal disease without aTBM antibodies, displayed reactivity with H3M-1. The possibility that the human aTBM antisera might recognize determinants in HSRTA other than H3M-I was then investigated. Fig. 3 , B and Cdemonstrate that whereas reactivity is quite strong with H3M-1, binding to HSRTA is much less, and column filtrate is almost completely depleted of reactivity (compared with normal human sera). This suggests that H3M-1 is the relevant moiety in HSRTA recognized by both patient antisera.
Sharedparatypic specificity between human and experimental animal aTBM antisera. In a solid-phase radioimmunoassay the ability of aTBM-Ab (IgG fraction) from experimental animals (immunized with rabbit tubular antigen) to inhibit binding of human aTBM antisera to R3M-I and H3M-1 was examined (Fig. 4, A and B) . aTBM-Ab eluted from the kidneys of both SJL mice and BN rats substantially inhibited the binding of human aTBM-Ab to H3M-1, as well as to R3M-1. Interestingly, with SJL aTBM-Ab, inhibition of binding to H3M-I was greater than that to R3M-1. Maximal inhibition ranged from 45 to 98%, and normal mouse and rat IgG were not inhibitory. Implicit in the fine analysis of the immunopathogenesis of an autoimmune disease is the definition of the target antigen. We have recently isolated from a complex rabbit renal tubular antigen preparation the glycoprotein responsible for inducing aTBM disease in experimental animals (8) . While a comparable disease entity is well described in patients, few data are currently available regarding the basic immunologic aspects of this renal lesion in humans, including the identification of the target antigen. Target The most detailed report which attempts to address this issue described a 70,000-mol-wt glycoprotein isolated from human TBM, and demonstrated that antisera from two patients with glomerulonephritis complicated by interstitial nephritis and linear aTBM immunofluorescence precipitated this moiety (16) . Whereas normal human sera did not react to any significant degree, the majority of patients with aGBM disease who also had aTBM linear immunofluorescence also recognized the TBM moiety. The possibility that the isolated TBM antigen was partially cross-reactive with the GBM could not be entirely excluded. Further, while this antigen elicited an immune response in BN rats, its relationship, if any, to heterologous antigens classically used to induce experimental aTBM disease was not analyzed. In addition, the specificity of the aTBM antisera, determined as differential recognition of BN, but not LEW, rat TBM was not evaluated. Finally, this study did not formally address the possibility that moieties within the TBM preparation other than the 70,000 mol-wt antigen were recognizable by the aTBM antisera.
We have previously reported on the 48,000-mol-wt nephritogenic antigen (R3M-1) ofexperimental aTBM disease (8) . This was isolated from a complex (> 15 bands on SDS-PAGE) rabbit renal tubular antigen preparation usually used to induce disease. R3M-1 is a noncollagenous glycoprotein localized to the most lateral aspects of the TBM. The present study also used immunoaffinity chromatography to isolate from normal human renal tissue a similarly sized moiety (H3M-1) which is the target antigen of aTBM-Ab from patients with well documented aTBM disease. Although one patient developed disease after renal transplantation and the other did so spontaneously, both patients had almost identical reactivity with H3M-1 by solidphase radioimmunoassay. Subtraction experiments demonstrated that the likely single recognition antigen in HSRTA is H3M-1. Neither pooled normal human sera, nor sera from seven patients with acute renal disease without aTBM antibodies recognized H3M-1. This latter group included two patients with primary interstitial nephritis and two patients with aGBM disease, indicating that an alH3M-1 response is not engendered nonspecifically as a part of interstitial nephritis and that H3M-1 is not cross-reactive with GBM determinants recognized by aGBM antisera. Several lines of evidence point to similarities between H3M-1 and R3M-1. First, not surprisingly, they are both recognized by the a3M-I monoclonal antibody, suggesting R3M-I shares at least one similar epitope with H3M-1. Second, patient antisera are highly reactive with both R3M-1 and H3M-1. Third, while the patient antisera stains TBM ofBN rat kidney in linear fashion, they are negative on LEW rat kidney, a strain generally acknowledged to be lacking the nephritogenic antigen of experimental aTBM disease. Lastly, antisera from experimental animals immunized with rabbit renal tubular antigen to produce aTBM disease competitively inhibit the binding of human aTBM antibody to R3M-1 and H3M-1. It is intriguing that aTBM-Ab from SJL mice are more effective at inhibiting the binding of human aTBM-Ab to H3M-I than to R3M-1. This suggests the possibility that human aTBM-Ab recognize some R3M-1 epitopes not seen by SJL antibodies. Alternatively, the human antibodies may recognize the same epitopes on R3M-1 that the mouse antibodies do, but the former antibodies do so with greater affinity.
It is, of course, impossible to state that H3M-1 is the target antigen ofhuman aTBM disease in all patients. This must await the evaluation of additional aTBM-Ab. Our findings, nevertheless, document an important and rare relationship between a human autoimmune renal lesion and its experimental counter-
